Reminder: Login to access new features and members-only content!

Register to be a member of our community. Its easy!

Register a new account

Already a member?

Log In here!

Donate

Did you find our content interesting or helpful? Help support the IPFD enhance health, well-being and welfare for dogs everywhere.

Jump to content

HGTD This week, 19 June 2020: NEW Orange Breed Relevance Rating (BRR)


Aimee Llewellyn-Zaidi

Viewed: 2,661 times

The continued review of breed-specific tests for assigning relevance ratings, and ongoing discussions with genetic experts has led to a refinement of the breed relevance ratings (please see: BRR) . To better accommodate the spectrum of genetic test validation, we’ve added a new orange BRR. 

The orange BRR indicates where all current available evidence has been reviewed, but the relevance is inconclusive. It could be that a mutation is detectable in a specific breed, but that there is no evidence that this correlates with clinical development of the disease/phene. It could also be that there is evidence that testing for the mutation does not correlate with the clinical development of the disease. One example is the wire-fox terrier and degenerative myelopathy. Despite research indicating a 94% mutation frequency (Zeng et. al, 2014) - meaning that practically every dog the researchers tested for SOD 1 mutation for degenerative myelopathy had 2 copies of the mutation - the development of the clinical signs of DM for the breed hasn't yet been reported. 

orange brr.png

 

 

 

 

 

In practical terms, this means that while you may still wish to test for the mutation in your breed, or it may be included on any testing panels, there isn’t currently a good reason to prioritize test results in any breeding or other health decisions. Unnecessarily excluding a dog from breeding based on irrelevant or inconclusive test results can be, on balance, very damaging to the genetic diversity of the breed. Thinking back to DM and the wire-fox terrier, this would mean that if breeding decisions were made on DM test results alone, you'd be excluding the vast majority of the dog population where the test does not for this breed seem to predict clinical disease. 

For any orange BRR, it would be worth looking at the test’s breed-specific information in more detail (search for test information HERE) to help put any potential test results into perspective. Wherever possible, the phenes database includes comments directly from the researchers and original test developers. As always, talk to your genetic test provider and/or veterinary scientist if you are concerned about genetic test results.  

And, if you missed it the first time around, you may want to check out the previous blog including updated breed relevance ratings, and breed-specific publications, HERE

References:

Zeng R., Coates J.R., Johnson G.C., Hansen L., Awano T., Kolicheski A., Ivansson E., Perloski M., Lindblad-Toh K., O'Brien D.P., Guo J., Katz M.L., Johnson G.S. (2014) Breed Distribution of SOD1 Alleles Previously Associated with Canine Degenerative Myelopathy. J Vet Intern Med 28: 515-521


Photo thanks to: Engin Akyurt, via Pexels

0 Comments


Recommended Comments

There are no comments to display.

Guest
Add a comment...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Blog Disclaimer
    The contents of this blog are for informational purposes only and represent the opinion of the author(s), and not that of the International Partnership for Dogs (IPFD). This is not intended to be a substitute for professional, expert or veterinarian advice, diagnosis, or treatment. We do not recommend or endorse any specific tests, providers, products, procedures, opinions, or other information that may be mentioned on, or linked to from this blog.

×
×
  • Create New...

Important Information

By using this site, you agree to our Terms of Use.